CN111378733A - Method for determining health food combination for neurodegenerative diseases and machine-readable storage medium thereof - Google Patents
Method for determining health food combination for neurodegenerative diseases and machine-readable storage medium thereof Download PDFInfo
- Publication number
- CN111378733A CN111378733A CN201811617777.7A CN201811617777A CN111378733A CN 111378733 A CN111378733 A CN 111378733A CN 201811617777 A CN201811617777 A CN 201811617777A CN 111378733 A CN111378733 A CN 111378733A
- Authority
- CN
- China
- Prior art keywords
- disease
- neurodegenerative disease
- nucleic acid
- combination
- health food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Public Health (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a method for determining a health food composition for neurodegenerative diseases and a machine-readable storage medium thereof. The method for determining the personalized health food composition for neurodegenerative diseases comprises the following steps. The nucleic acid detecting step is to detect the nucleic acid in the biological sample and judge the possibility of suffering from the neurodegenerative disease according to the detection result of the nucleic acid. The disease detection step is to detect the target and at least one health index in the blood sample, and judge that the neurodegenerative disease does not exist according to the detection result of the target. The personalized neurodegenerative disease health food combination determining step determines the personalized neurodegenerative disease health food combination according to the possibility of suffering from the neurodegenerative disease in the nucleic acid detecting step and at least one health index in the disease detecting step, wherein the personalized neurodegenerative disease health food combination comprises a plurality of health foods, and at least one health food is immunomodulatory protein or a compound of immunomodulatory proteins.
Description
Technical Field
The invention relates to a method for determining a personalized health-care food composition for neurodegenerative diseases and a non-transitory computer readable storage medium.
Background
Neurodegenerative diseases, also known as neurodegenerative diseases, are long-term diseases caused by the gradual death of neuronal cells or their myelin sheaths of the central nervous system of an individual. Neuronal and myelin cells of the central nervous system cannot regenerate under normal physiological conditions, and thus, once the neuronal or myelin cells die massively, irreversible damage to the central nervous system will occur. Although there are individual phenotypes or characteristics of different types of neurodegenerative diseases, in any case, symptoms of neurodegenerative diseases become apparent as time accumulates and often worsen over time, thereby causing memory, cognitive or motor function impairment in an individual. Because neurodegenerative diseases usually take a long time before obvious symptoms appear, patients often take years or even decades before physiological functions are affected. At this point, the central nervous system of the patient has experienced a substantial cessation of cell function and even cell death, and the brain often begins to lose partial function.
However, when the symptoms affecting the normal physiological functions of the patients appear, the treatment is usually slow and inconvenient, at most, the current situation can be maintained, the damage to the central nervous system of the patients cannot be reversed, and the worsening process of the symptoms can be delayed. It follows that the threat of neurodegenerative diseases to human health has reached a non-negligible level. In recent years, molecular medicine science and technology have gradually developed neurodegenerative disease gene markers for risk diagnosis and prediction of neurodegenerative diseases, and gene detection can detect gene variation at an early stage and understand the possibility of suffering from neurodegenerative diseases in individuals. Furthermore, there are many different methods for testing whether a subject has suffered from a neurodegenerative disease, such as blood physiological markers, psychological tests, Magnetic Resonance Imaging (MRI), positron emission tomography, etc., and if the subject has suffered from a neurodegenerative disease, entering into the course of treatment; if the subject does not suffer from a neurodegenerative disease, no subsequent medical action is performed.
Although many health foods are available for health care of neurodegenerative diseases, the health foods are mostly used for providing a patient supporting therapeutic effect after the disease occurs, and the prepositive health care is relatively less. However, as mentioned above, it is often not quick to start taking the health food until the patient actually gets ill. And the prepositive health care measures are taken even in the non-morbidity stage according to the constitution and the health state of each individual, and if the health care food is not provided according to the individual difference only according to the type of the neurodegenerative disease, the prepositive health care effect which can be exerted is actually quite limited.
Therefore, it is an important object to provide a method for determining a personalized health food composition suitable for an individual when the individual is known to have a possibility or risk of a neurodegenerative disease based on a correlation test and the individual can be provided with a suitable composition for the individual according to the constitution of the individual.
Disclosure of Invention
In view of the above problems, the present invention provides a method for determining a personalized health food composition for individuals likely to suffer from neurodegenerative diseases.
To achieve the above object, the present invention provides a method for determining a personalized health food composition for neurodegenerative diseases, which is provided for individuals likely to suffer from neurodegenerative diseases. The method comprises the following steps: (1) a nucleic acid detection step of detecting nucleic acid in a biological sample of an individual and judging whether the individual has the possibility of suffering from neurodegenerative diseases or not according to the detection result of the nucleic acid; (2) a disease detection step of detecting a target (target) and at least one health index in a blood sample of the subject, the target corresponding to the neurodegenerative disease and determining that the neurodegenerative disease is not present according to a detection result of the target; and (3) a health food combination determination step of determining a personalized health food combination for neurodegenerative diseases according to the possibility of suffering from neurodegenerative diseases in the nucleic acid detection step and the health index in the disease detection step. The personalized health food composition for neurodegenerative diseases comprises a plurality of health foods, wherein at least one health food is immunomodulatory protein or a composite of immunomodulatory proteins.
In one embodiment, the biological sample is a human bodily fluid, human blood, or human interstitial fluid.
In one embodiment, the aforementioned immunomodulatory protein is a microsporum immunomodulatory protein (GMI).
In one embodiment, the aforementioned health index comprises at least a blood cell index, a blood glucose index, a blood fat index, a liver function index, a kidney function index, or a pancreas function index.
In one embodiment, the neurodegenerative disease is alzheimer's disease, frontotemporal dementia, parkinson's disease, or huntington's disease.
In one embodiment, the nucleic acid is a gene selected from the group consisting of APP, PSEN1, PSEN2, APOE4, MAPT, TDP-43, C9orf72, SNCA, PRKN, PARK8, PINK1, ATP13A2 or HTT, or any combination thereof, and the target is the CAG repeat number of the α -synuclein, Hb, MCV, GOT/GPT, BUN/Cr, TSH/T3/T4, B12 or Huntingtin genes, or any combination thereof.
In one embodiment, when the neurodegenerative disease is alzheimer's disease, the nucleic acid is a gene of APP, PSEN1, PSEN2, or APOE4, or any combination thereof. And the target is Hb, MCV, GOT/GPT, BUN/Cr, TSH/T3/T4 or B12, or any combination of the foregoing targets.
In one embodiment, when the neurodegenerative disease is frontotemporal dementia, the nucleic acid is MAPT, TDP-43, or C9orf72, or any combination thereof. And the target is Hb, MCV, GOT/GPT, BUN/Cr, TSH/T3/T4 or B12, or any combination of the foregoing targets.
In one embodiment, when the neurodegenerative disease is Parkinson's disease, the nucleic acid is a gene selected from the group consisting of SNCA, PRKN, PARK8, PINK1, and ATP13A2, or any combination thereof, and the target is α -synuclein, Hb, MCV, GOT/GPT, BUN/Cr, TSH/T3/T4, and B12, or any combination thereof.
In one embodiment, when the neurodegenerative disease is Huntington's disease, the nucleic acid is HTT and the target is the number of CAG repeats of the Huntingin gene.
The invention also provides a non-transitory computer readable storage medium storing a plurality of instructions executable by a processing unit of a computer device to determine detection data or detection data of the steps of the method and determine the personalized health food combination for neurodegenerative disease.
In summary, the method for determining a personalized health food composition for neurodegenerative diseases and the non-transitory computer readable storage medium for performing the method of the present invention can provide a personalized health food composition for neurodegenerative diseases that meets the requirements of the individual for their constitutions and health according to the possibility of suffering from neurodegenerative diseases and their health status when the individual is not suffering from neurodegenerative diseases.
Drawings
Fig. 1 is a flowchart illustrating a method for determining a personalized health food composition for neurodegenerative diseases according to a first embodiment of the present invention.
Fig. 2 is a non-transitory computer readable storage medium for determining a personalized neurodegenerative disease health food combination according to a second embodiment of the present invention.
Detailed Description
Various embodiments provided in accordance with the present invention will now be described with reference to the accompanying drawings, wherein like components are designated by like reference numerals.
It should be noted that all the directional indicators (such as upper, lower, left, right, front and rear …) in the embodiments of the present invention are only used to explain the relative position relationship between the components, the motion situation, etc. in a specific posture (as shown in the attached drawings), and if the specific posture is changed, the directional indicator will be changed accordingly.
It should be noted that while the following examples of the present invention are provided to illustrate one possible combination of the disclosed components, the present invention is intended to include all possible combinations of the disclosed components. Thus, if one embodiment includes components A, B and C and a second embodiment includes components B and D, the present invention should be understood to include any combination of A, B, C and/or other species of D, even if not explicitly disclosed.
In certain embodiments described below, where numerical values are described that indicate quantities of ingredients, characteristics (e.g., concentrations, reaction conditions, etc.), it is to be understood that the term "about" is used in some instances to modify. Accordingly, in certain embodiments, the numerical parameters set forth in this specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by a particular embodiment. In some embodiments, numerical parameters should be construed in light of the number of significant digits recited and by applying ordinary numerical reduction techniques. However, even though some of the examples show some approximations, the numerical ranges and numerical parameters set forth in the specific examples are reported as precisely as possible. The numerical values set forth herein may include certain errors resulting from the standard deviation found in the statistics of the various measurements.
Unless otherwise specified herein, all numerical ranges set forth herein are to be construed as inclusive of their endpoints, and open-ended ranges are to be construed as inclusive of commercially practicable values. Likewise, all numerical lists should be considered as containing the numerical values therein between unless otherwise specified herein. That is, recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated, each separate value within a range is incorporated into a portion of the disclosure of this specification as if it were individually recited herein.
The group of alternative components or embodiments disclosed herein should not be construed as limiting the invention. Each member of a group may be referred to and claimed individually or in any combination with other members of the group or with other components herein. For reasons of convenience and/or patentability, one or more members of the group may be included in or deleted from the group. When any of the foregoing additions or deletions occur, the specification is to be considered as including the modified group so as to satisfy the written description requirements of all markush groups used in the appended claims. And any terms in the specification should not be construed as essential to the practice of the invention, even if not explicitly recited in the claims.
As used herein, the terms "individual", "subject" and "patient" can be a human or non-human mammal. Non-human mammals include, for example, domestic animals and pets, such as ovine, bovine, porcine, canine, feline, and murine mammals. Preferably, the subject is a human. The terms "individual" and "individual" may be used interchangeably.
The term "biological sample" refers to a sample obtained from an organism or a component of an organism (e.g., a cell). The sample may be any biological tissue or fluid. Samples include, but are not limited to, bone marrow, sputum, whole blood, serum, plasma, lymph, corpuscular cells (e.g., red blood cells), urine, peritoneal fluid, and pleural fluid or cells from these samples. The biological sample may also include portions of tissue, such as frozen sections taken for histological purposes. Preferably, the biological sample is a body fluid, blood, or interstitial fluid.
The term "blood sample" includes, but is not limited to, whole blood, serum, plasma, lymph fluid, or corpuscular cells (e.g., red blood cells). Preferably, the biological sample is whole blood.
The term "nucleic acid," such as DNA or RNA, refers to an isolated nucleic acid. The term "isolated" refers to a DNA or RNA molecule that is correspondingly isolated from other DNA or RNA present in the natural source of the macromolecule.
The term "health index" refers to an index generally examined by routine examination of blood, including, but not limited to, a blood cell index, a blood glucose index, a blood fat index, a liver function index, a kidney function index, and a pancreas function index.
The term "mutation" includes, but is not limited to, a Single Nucleotide Polymorphism (SNP), insertion, deletion, rearrangement or point mutation.
Referring to fig. 1, fig. 1 is a schematic flow chart of a providing method of a health food composition for neurodegenerative diseases according to a first embodiment of the present invention. As shown in the figure, S1 is a nucleic acid detection step, S2 is a disease detection step, S3 is a personalized neurodegenerative disease health food combination determination step, and S4 is an end step.
As shown in the drawings, the method for determining a personalized health food composition for neurodegenerative diseases according to the first embodiment of the present invention is provided for individuals who may suffer from neurodegenerative diseases. The determination method of the present embodiment includes the following steps. Nucleic acid detection step S1: in this step, the nucleic acid in a biological sample is detected, and the biological sample may be an isolated (or non-living) sample isolated from a human individual, and may be a body fluid (e.g., sweat or urine), blood, or tissue fluid thereof. Meanwhile, whether the individual corresponding to the biological sample has the possibility of suffering from the neurodegenerative disease or not is judged according to the detection result of the nucleic acid. The detection method may be performed by a gene chip, PCR, quantitative PCR, Next Generation Sequencing (NGS), or the like. If the subject has a likelihood of suffering from a neurodegenerative disease, then proceed to step S2; if the subject is not likely to suffer from a neurodegenerative disease, step S4 is entered to end the method identified herein. In this step, if the subject does not have a possibility of suffering from the corresponding neurodegenerative disease according to the detection result, it indicates that the subject is at low risk of suffering from the neurodegenerative disease, and therefore, it is not necessary to further determine whether or not the subject actually suffers from the corresponding neurodegenerative disease.
Next, when the subject has a possibility of suffering from the neurodegenerative disease, a disease detection step S2 is performed: in this step, the target and at least one health index in the blood sample of the subject are detected, and whether the subject has suffered from the neurodegenerative disease is judged according to the detection result of the target; the target corresponds to the neurodegenerative disease. If the subject does not suffer from the neurodegenerative disease, go to step S3; if the subject already suffers from the neurodegenerative disease, step S4 is entered to end the determination method. Thus, through steps S1 and S2 of the method provided in this embodiment, an individual who has a possibility of suffering from the neurodegenerative disease but who has not yet suffered from the neurodegenerative disease has been identified. As can be seen from the above, the steps S1 and S2 of the method of the present embodiment can establish the time period that the subject is suitable for receiving the personalized health food combination for neurodegenerative diseases.
In addition, the health index detected in this step S2 may be or include at least one index of a blood cell index, a blood glucose index, a blood fat index, a liver function index, a kidney function index, or a pancreas function index. A hematocrit index is, for example, but not limited to, white blood cells, red blood cells, hemoglobin, average corpuscular volume, platelets, or other hematocrit index known to those skilled in the art. Glycemic indices such as, but not limited to, pre-prandial blood glucose, post-prandial blood glucose, glycated hemoglobin, or other glycemic indices known to those of skill in the art. The blood fat index is such as, but not limited to, cholesterol, triglycerides, high density lipoprotein cholesterol, low density lipoprotein cholesterol, or other blood fat indices known to those skilled in the art. Liver function index such as but not limited to GOT (glutamic acid oxalate transferase), GPT (pyruvate transferase), GGT (glutamic acid transferase), ALK-P (alkaline phosphatase), T-BIL (total bilirubin) or other known liver function index by those skilled in the art. Renal function indices such as, but not limited to, BUN (urea nitrogen), CREA (creatinine), UA (uric acid), or other renal function indices known to those skilled in the art. Pancreatic function index such as, but not limited to, AMY (amylase), LIPASE (LIPASE) or other pancreatic function index known to those skilled in the art.
In summary, if the individual does not suffer from the neurodegenerative disease, the personalized neurodegenerative disease health food combination determination step S3 is performed: in this step, if the individual does not have neurodegenerative disease and has a possibility of having neurodegenerative disease, it is determined from the results of steps S1 and S2 that the personalized neurodegenerative disease health food composition is determined according to at least one of the possibility of having neurodegenerative disease in the nucleic acid detecting step and the health index of the disease detecting step. The personalized health food composition for neurodegenerative diseases comprises a plurality of health foods, wherein at least one health food is immunomodulatory protein or a composite of immunomodulatory proteins. It is further noted that, in this step, the health food items other than the immunomodulatory protein or the immunomodulatory protein complex in the personalized neurodegenerative disease health food composition are determined based on the health index measured in step S2. That is, the health index measured in step S2 is used to determine the health food for neurodegenerative disease suitable for the constitution and/or current health condition of the subject. In addition, the methods of determining a personalized neurodegenerative disease health food combination of the present invention are non-therapeutic and/or suitable for providing further health care to an individual who is not diseased.
In this embodiment, the aforementioned immunomodulatory protein may be Ganoderma microsporum immunomodulatory protein (GMI). The immunomodulatory proteins used in this example (e.g., the microsporoGanoderma immunomodulatory proteins disclosed in TW I414307 and TW 201625286) have effects in promoting growth of neurites and dendrites of nerve cells. It can protect neurons and repair damaged neurons by inhibiting the generation of Reactive Oxygen Species (ROS), and improve the spatial memory disorder caused by brain damage of individuals. Therefore, the immunomodulatory protein is suitable for being used as health food for neurodegenerative diseases.
Therefore, after the subject receives the personalized health food combination for neurodegenerative diseases containing the immunomodulatory protein (which may also be a compound or compound product of the immunomodulatory protein) determined in step S3 and starts to take the composition, the subject can obtain a personalized health food combination (required by the physical fitness and/or the health status of the subject) due to the other health foods for neurodegenerative diseases determined according to the health index in the disease detection step, in addition to the health effect of the immunomodulatory protein itself.
In this embodiment, the neurodegenerative disease may be Alzheimer's disease, frontotemporal dementia, Parkinson's disease, or Huntington's disease, and the nucleic acid may be or may comprise APP (amyloid beta protein, pre-amyloid protein gene), PSEN1(presenilin 1, presenilin 1 gene), PSEN2(presenilin 2, presenilin 2 gene), APOE4(apolipoprotein E epsilon 4, lipocalin epsilon 4 gene type E), MAPT (microtubular assoidopedprotein tau, microtubule-associated protein gene), TDP-43(TAR DNA binding protein, TAR DNA binding protein gene), C9orf72(chromosome 9open 9 gene 72, 9 chromosome open reading frame 72), SNCA (alpha), PRkinetin (GOK 3), or a protein coding protein (ATP coding protein), or a protein coding protein, or a protein (coding protein), or a protein, or a combination of at least one of the aforementioned genes, such as protein, protein.
Taking alzheimer 'S disease as an example, if the aforementioned neurodegenerative disease is alzheimer' S disease, the nucleic acid to be detected in the nucleic acid detecting step S1 is or may include a nucleic acid of at least one gene of APP, PSEN1, PSEN2 or APOE4, and the target is or may include at least one target of Hb (Hemoglobin), MCV (mean corpuscular volume), GOT/GPT (Glutamic Oxaloacetic tranamic transferase/Glutamic paramagnetic transferase), BUN/Cr (Blood Urea nitrate/creeine), TSH/T3/T4 (viscous-stimulating hormone T3/T4), or vitamin B12. For example, if the nucleic acid APP (amyloid beta precorsoprotein) is a gene of the pre-amyloid protein and mutations occur in the gene of the pre-amyloid protein or in a position important for the upstream and downstream regulatory transcriptional or translational functions, the probability of Alzheimer's disease in the subject is increased. Similarly, PSEN1(presenilin 1), PSEN2(presenilin 2, presenilin 2) and APOE4(apolipoproteinE epsilon 4) were also found to have a higher chance of developing Alzheimer's disease or at an earlier time if the individual had mutations or had a higher copy number than normal individuals. In addition, the targets Hb (hemoglobin) and (hemoglobin) are used to detect hemoglobin, MCV (mean corpuscular volume) and (GOT/GPT) and (liver function) and (BUN/Cr (Blood Urea Nitrogen/Creatinine) and (TSH/T3/T4 (magnetic-stimulating hormone T3/T4) and (vitamin B12) respectively And/or positive sub-photography to comprehensively determine whether the individual may already suffer from Alzheimer's disease. If the individual detects the mutation of the gene and fails to determine that the patient has developed the disease according to the disease detection result, the individual is likely to suffer from the Alzheimer's disease but does not suffer from the Alzheimer's disease, and the personalized health food combination for neurodegenerative disease is determined according to the Alzheimer's disease and the health index of the individual. The health food composition for neurodegenerative diseases at least comprises immunomodulatory protein or a complex of immunomodulatory proteins, and health food for neurodegenerative diseases, such as but not limited to Lecithin (Lecithin), antioxidant vitamins (e.g. vitamin A, C, E …, etc.), Ginkgo biloba extract (Ginkgo-biloba extract), Omega-3 fatty acid (e.g. docosahexaenoic acid (DHA), fish oil), etc., or any combination of the foregoing.
For example, if the aforementioned neurodegenerative disease is frontotemporal dementia, the nucleic acid to be detected in the nucleic acid detecting step S1 is or may include a nucleic acid of at least one gene of mapt (minor associated protein tau), TDP-43(TAR DNA binding protein) or C9orf72(chromosome 9 reading frame 72, chromosome 9open reading frame 72), and the target is or may include at least one target of Hb, MCV, GOT/GPT, BUN/Cr, TSH/T3/T4 or vitamin B12. For example, the nucleic acid mapt (microtubule-associated protein tau) is a gene encoding microtubule-associated protein tau, which, if mutated to result in hyperphosphorylation of microtubule-associated protein tau, destabilizes microtubules in neuronal axons, rendering the neurons unable to function normally, thereby increasing the likelihood of developing frontotemporal dementia. Similarly, TDP-43(TAR DNA binding protein) or C9orf72(chromosome 9open reading frame 72) was also found to have a higher chance of developing frontotemporal dementia if mutated. In addition, the target Hb (hemoglobin) is for detecting hemoglobin, MCV (Blood corpuscle volume) is for detecting average corpuscular volume, GOT/GPT (Glutamic oxaloacetic tranminatinase/Glutamic pyrolic tranminase) is for detecting liver function, BUN/Cr (Blood Ureagentogen/Creatinine) is for detecting kidney metabolic function, TSH/T3/T4 (toxic-stimulating hormone T3/T4) and vitamin B12 are for detecting Thyroid function, and further, a syphilis serum reaction test (VDRL) may be performed simultaneously when performing a Blood test to exclude the possibility that the individual has a symptom of nerve damage due to infection, and a detector may perform a Magnetic Resonance Imaging (MRI) based on the result of a disease test (for example, but not limited to, the concentration of the sample in the Blood sample is increased or decreased), or the target MRI is performed simultaneously, or the psychological resonance imaging (MRI) is performed simultaneously, to comprehensively judge whether the individual is likely to suffer frontotemporal dementia. If the individual detects the mutation of the gene and fails to determine that the patient has the disease according to the disease detection result, the individual has the possibility of suffering frontotemporal dementia but does not suffer frontotemporal dementia, and the personalized health food combination for the neurodegenerative disease is determined according to the frontotemporal dementia and the health index of the individual. The health food composition for neurodegenerative diseases at least comprises immunomodulatory protein or a complex of immunomodulatory proteins, and health food for neurodegenerative diseases, such as but not limited to Lecithin (Lecithin), antioxidant vitamins (e.g. vitamin A, C, E …, etc.), Ginkgo biloba extract (Ginkgo-biloba extract), Omega-3 fatty acid (e.g. docosahexaenoic acid (DHA), fish oil), etc., or any combination of the foregoing.
In the case of Parkinson ' S disease, if the aforementioned neurodegenerative disease is Parkinson ' S disease, the nucleic acid to be detected in the nucleic acid detection step S1 is or may comprise at least one gene selected from SNCA (synuclein alpha), PRKN (parkin RBR E3 ubietin ligand), PARK8 (leucoine rich repeat kinase 2, also known as LRRK2), PINK1 (PTENNDuculated kinase 1), ATP13A2(ATPase trapping transport 13A2) and the target may or may not comprise α -synuclein, Hb, MCV, GOT/GPT, BUN/Cr, TSH 3/T4 or at least one target of the aforementioned glutathione protein, such as a protein found in a clinical test for the presence of a synuclein or a protein that is detected in a clinical test for the aforementioned neurolysis/protein loss of Blood or a liver function, and/protein found in subjects who have not detected a clinical test for the aforementioned hypertension, such as a prostate-protein degradation/protein accumulation or a liver function regulation of Parkinson ' S disease (TSK-protein), or a liver dysfunction, such as a liver dysfunction, or a liver dysfunction test for which is determined by a clinical test for example, a clinical test for a protein accumulation of a protein found in individuals with a prostate-degrading protein (sperm-protein, or a liver dysfunction, or a liver dysfunction, a protein found in a food-degrading protein (a food-protein not associated with a clinical test for which is or a liver dysfunction, such as a cardiovascular dysfunction, or a cardiovascular dysfunction, or a cardiovascular dysfunction, a cardiovascular dysfunction test for example, a cardiovascular dysfunction (a cardiovascular dysfunction, a cardiovascular dysfunction test for example, a cardiovascular dysfunction (a cardiovascular dysfunction test for example, a cardiovascular dysfunction of a patient may or a cardiovascular dysfunction, a patient may or a cardiovascular dysfunction of a cardiovascular dysfunction test for example, a cardiovascular dysfunction of a patient may not indicated by a cardiovascular dysfunction of a cardiovascular dysfunction, a cardiovascular dysfunction of a patient, a patient may not indicated by a patient, a cardiovascular dysfunction, a patient, a cardiovascular dysfunction test for example, a patient, a cardiovascular dysfunction, a patient may not indicated by a cardiovascular dysfunction, a cardiovascular dysfunction of a cardiovascular dysfunction, a patient, a cardiovascular dysfunction, a patient may or a patient, a cardiovascular dysfunction, a patient may or a cardiovascular dysfunction, a patient may or a patient, a cardiovascular dysfunction, a patient may or.
Similarly, if the aforementioned neurodegenerative disease is huntington' S disease, the nucleic acid to be detected in the nucleic acid detecting step S1 is htt (Huntingtin), and the target is the number of repeats or copy number of CAG sequence (CAG motif) in Huntingtin gene. For example, the HTT (huntingtin) gene is mutated and is believed to be highly associated with Huntington's disease. In addition, when the number of repeats or copy number of the CAG sequence (CAG motif) in the target Huntingtin gene is higher than a normal value (threshold), this is often an indication that the individual has huntington's disease. The medical examiner comprehensively determines whether the individual may have huntington's disease or not according to the increase/decrease or the presence of the concentration or index of the target in the blood sample, and the detection of the relevant clinical symptoms, psychological tests, Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and/or orthophoto. If the individual detects the mutation of the gene and the disease detection result fails to conclude that the patient has the disease, the individual is likely to suffer from Huntington's disease but not suffer from Huntington's disease, and the personalized health food combination for neurodegenerative disease is determined according to the Huntington's disease and the health index of the individual. The health food composition for neurodegenerative diseases at least comprises immunomodulatory protein or a complex of immunomodulatory proteins, and health food for neurodegenerative diseases, such as but not limited to Lecithin (Lecithin), antioxidant vitamins (e.g. vitamin A, C, E …, etc.), Ginkgo biloba extract (Ginkgo-biloba extract), Omega-3 fatty acid (e.g. docosahexaenoic acid (DHA), fish oil), etc., or any combination of the foregoing.
In addition, the present invention also provides a second embodiment, which is a non-transitory computer readable storage medium to determine a personalized list of health foods.
As shown in fig. 2, the non-transitory computer readable storage medium of the present embodiment is executed by the computer device 10 and is used for determining and providing the personalized health food list. The computer device 10 of the present embodiment includes a storage unit 101, one or more processing units 102, a communication unit 103, a display unit 104, an input unit 105, and a housing (not shown), wherein the storage unit 101, the processing unit 102, and the communication unit 103 are disposed in the housing of the computer device 10. In the embodiment, the drawings are simplified, and the number of the processing units 102 is illustrated by taking one as an example.
The processing unit 102 is coupled to the storage unit 101, the communication unit 103, the display unit 104, and the input unit 105, and is configured to execute instructions (e.g., program code) to perform the method for providing personalized health food as described above. The processing unit 102 is, for example, a processor capable of executing instructions (e.g., program code), each of which may include one or more cores. The storage unit 101 may be a random access memory or a non-volatile computer-readable storage medium, such as a hard disk, a Solid State Disk (SSD), a flash memory, an optical disk, a computer tape, or any combination thereof. The Memory may include a Read Only Memory (ROM), a Flash Memory (Flash Memory), or other forms of non-transitory Memory such as a Field-Programmable Gate Array (FPGA). The memory unit 101 stores instructions (e.g., program codes) 101a executable by the processing unit 102. for simplicity, fig. 2 illustrates two instructions 101a in the memory unit 101, which are not intended to limit the present invention. The communication unit 103 is a device capable of providing network connection, such as a network card, a network chip, and a modem. The display unit 104 includes a display adapter, a display chip, a display, and the like, and the input unit 105 is, for example, a keyboard, a mouse, a touch screen, or the like.
The processing unit 102 reads the instruction (e.g., program code) 101a from the storage unit 101 and executes it to perform the following operations: (1) and judging the detection result of the nucleic acid. After the nucleic acid in the biological sample of the individual is detected by the aforementioned method to obtain the detection data (or result) of the nucleic acid, and the processing unit 102 receives the detection data (or result) of the nucleic acid inputted via the input unit 105, the processing unit 102 performs the step of determining the detection result of the nucleic acid: the processing unit 102 determines whether the subject has a possibility of suffering from a neurodegenerative disease according to the data (or result) of the detection of the nucleic acid. (2) And judging the disease detection result. After detecting the target (target) and at least one health index in the blood sample of the individual by the aforementioned method to obtain the target detection data (or result) and the health index, and the processing unit 102 receives the detection data (or result) of the target and the health index inputted by the input unit 105, the processing unit 102 performs the step of determining the disease detection result: the processing unit 102 determines whether the subject has suffered from the neurodegenerative disease according to the detected data (or result) of the target. And the target corresponds to the aforementioned neurodegenerative disease. And (3) a health food composition determination step for neurodegenerative diseases. If the processing unit 102 determines that the subject does not have a neurodegenerative disease and has a possibility of having a neurodegenerative disease, the processing unit 102 performs the step of determining a neurodegenerative disease health food combination: the processing unit 102 determines the personalized neurodegenerative disease health food combination according to the possibility of suffering from neurodegenerative disease in the nucleic acid detecting step and the health index in the disease detecting step. The personalized health food composition for neurodegenerative diseases comprises a plurality of health foods, wherein at least one health food is immunomodulatory protein or a composite of immunomodulatory proteins. For example, the method of nucleic acid detection may be performed by a gene chip, PCR, quantitative PCR, Next Generation Sequencing (NGS), etc., and the step of determining the result of nucleic acid detection in the embodiment determines whether the subject has the possibility of suffering from neurodegenerative disease according to the result (e.g., data) detected by the method; the detecting method of neurodegenerative disease may be blood detection, image detection, etc., and the determining step of detecting the result of neurodegenerative disease in the present embodiment determines whether the subject has suffered from neurodegenerative disease according to the result (e.g., data, image, etc.) detected by the detecting method.
Other technical features of the non-transitory computer readable storage medium of this embodiment are the same as those described in the previous embodiment, and reference may be made to the description related to the method for determining a personalized health food for neurodegenerative diseases in the first embodiment of the present invention, which is not repeated herein.
In summary, the present invention provides a method for determining a personalized neurodegenerative disease health food combination and a non-transitory computer readable storage medium for performing the method, which can provide a personalized neurodegenerative disease health food combination meeting the physical and health requirements of an individual according to the possibility of suffering from a neurodegenerative disease and the health status of the individual when the individual is not suffering from the neurodegenerative disease.
The foregoing is by way of example only, and not limiting. It is intended that all equivalent modifications or variations not departing from the spirit and scope of the present invention shall be included in the appended claims.
Claims (11)
1. A method of determining a personalized neurodegenerative disease health food combination for use by an individual likely to suffer from a neurodegenerative disease, the method comprising:
a nucleic acid detection step of detecting nucleic acid in a biological sample and judging the possibility of suffering from neurodegenerative diseases according to the detection result of the nucleic acid;
a disease detection step of detecting a target and at least one health index in the blood sample, wherein the target corresponds to the neurodegenerative disease, and judging whether the neurodegenerative disease is not suffered according to the detection result of the target; and
a neurodegenerative disease health food combination determining step of determining a personalized neurodegenerative disease health food combination comprising a plurality of health foods, wherein at least one health food is an immunomodulatory protein or a complex of immunomodulatory proteins, based on the likelihood of suffering from the neurodegenerative disease in the nucleic acid detecting step and the at least one health index in the disease detecting step.
2. The method of claim 1, wherein the biological sample is a human bodily fluid, human blood, or human interstitial fluid.
3. The method of claim 1, wherein the immunomodulatory protein is microsporo ganoderma immunomodulatory protein (GMI)).
4. The method of claim 1, wherein the health index comprises at least a blood cell index, a blood glucose index, a blood fat index, a liver function index, a kidney function index, or a pancreas function index.
5. The method of claim 1, wherein the neurodegenerative disease is alzheimer's disease, frontotemporal dementia, parkinson's disease, or huntington's disease.
6. The method of claim 5, wherein the nucleic acid is APP, PSEN1, PSEN2, APOE4, MAPT, TDP-43, C9orf72, SNCA, PRKN, PARK8, PINK1, ATP13A2, HTT, or a combination thereof, and the target is α -synuclein, Hb, MCV, GOT/GPT, BUN/Cr, TSH/T3/T4, B12, Huntingin gene CAG repeat number, or a combination thereof.
7. The method of claim 5, wherein when the neurodegenerative disease is alzheimer's disease, the nucleic acid is APP, PSEN1, PSEN2, APOE4, or a combination thereof, and the target is Hb, MCV, GOT/GPT, BUN/Cr, TSH/T3/T4, B12, or a combination thereof.
8. The method of claim 5, wherein when the neurodegenerative disease is frontotemporal dementia, the nucleic acid is MAPT, TDP-43, C9orf72, or a combination thereof, and the target is Hb, MCV, GOT/GPT, BUN/Cr, TSH/T3/T4, B12, or a combination thereof.
9. The method of claim 5, wherein when the neurodegenerative disease is Parkinson's disease, the nucleic acid is SNCA, PRKN, PARK8, PINK1, ATP13A2, or a combination thereof, and the target is α -synuclein, Hb, MCV, GOT/GPT, BUN/Cr, TSH/T3/T4, B12, or a combination thereof.
10. The method of claim 5, wherein when the neurodegenerative disease is Huntington's disease, the nucleic acid is HTT and the target is Huntingin gene CAG repeat number.
11. A non-transitory computer readable storage medium storing a plurality of instructions for execution by a processing unit of a computer device to determine inspection data or inspection data for the steps of the method of any one of claims 1 to 10 and determine the personalized neurodegenerative disease health food combination.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811617777.7A CN111378733A (en) | 2018-12-28 | 2018-12-28 | Method for determining health food combination for neurodegenerative diseases and machine-readable storage medium thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811617777.7A CN111378733A (en) | 2018-12-28 | 2018-12-28 | Method for determining health food combination for neurodegenerative diseases and machine-readable storage medium thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111378733A true CN111378733A (en) | 2020-07-07 |
Family
ID=71216510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811617777.7A Withdrawn CN111378733A (en) | 2018-12-28 | 2018-12-28 | Method for determining health food combination for neurodegenerative diseases and machine-readable storage medium thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111378733A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005008555A1 (en) * | 2003-07-11 | 2005-01-27 | Sciona Limited | Computer-assisted means for providing personalised healthcare products |
| US20100028356A1 (en) * | 2007-02-08 | 2010-02-04 | Powmri Ltd. | Method of diagnosing a neurodegenerative disease |
| US20100042438A1 (en) * | 2008-08-08 | 2010-02-18 | Navigenics, Inc. | Methods and Systems for Personalized Action Plans |
| US20130116179A1 (en) * | 2011-09-01 | 2013-05-09 | University Of Ulster | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| CN106461645A (en) * | 2014-04-07 | 2017-02-22 | 铁马诊断公司 | Traumatic brain injury and neurodegenerative biomarkers, methods, and systems |
| US20170198349A1 (en) * | 2014-06-24 | 2017-07-13 | Alseres Neurodiagnostics, Inc. | Predictive neurodiagnostic methods |
-
2018
- 2018-12-28 CN CN201811617777.7A patent/CN111378733A/en not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005008555A1 (en) * | 2003-07-11 | 2005-01-27 | Sciona Limited | Computer-assisted means for providing personalised healthcare products |
| US20100028356A1 (en) * | 2007-02-08 | 2010-02-04 | Powmri Ltd. | Method of diagnosing a neurodegenerative disease |
| US20100042438A1 (en) * | 2008-08-08 | 2010-02-18 | Navigenics, Inc. | Methods and Systems for Personalized Action Plans |
| US20130116179A1 (en) * | 2011-09-01 | 2013-05-09 | University Of Ulster | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| CN106461645A (en) * | 2014-04-07 | 2017-02-22 | 铁马诊断公司 | Traumatic brain injury and neurodegenerative biomarkers, methods, and systems |
| US20170198349A1 (en) * | 2014-06-24 | 2017-07-13 | Alseres Neurodiagnostics, Inc. | Predictive neurodiagnostic methods |
Non-Patent Citations (6)
| Title |
|---|
| WIDER C等，: "Etiology and Pathophysiology of Frontotemporal Dementia, Parkinson Disease and Alzheimer Disease", 《NEURODEGENERATIVE DISEASES》 * |
| 刘颖等: "高血糖与阿尔茨海默病关系研究进展", 《实用老年医学》 * |
| 林勇等: "阿尔茨海默病与甲状腺激素 血脂关系的研究进展", 《安徽医学》 * |
| 王春玉等: "Alzheimer病血清胆固醇、血脂、叶酸、VB_(12)及甲状腺激素变化的临床研究", 《中国老年学杂志》 * |
| 郭盼等: "阿尔茨海默病与甲状腺功能相关性的研究进展", 《实用老年医学》 * |
| 陈谊颖: "探讨小孢子灵芝免疫调节蛋白GMI在STZ诱导糖尿病小鼠之伤口癒合治疗效果", 《台北医学大学医学科学研究所学位论文》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| He et al. | Sex-specific reference intervals of hematologic and biochemical analytes in Sprague-Dawley rats using the nonparametric rank percentile method | |
| Zacharoff et al. | Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease | |
| Locascio et al. | Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson’s disease | |
| CN102762986B (en) | The diagnostic method of Alzheimer disease | |
| CN107217089B (en) | Method and device for determining individual state | |
| Gaffney et al. | Wilson's disease: acute and presymptomatic laboratory diagnosis and monitoring | |
| CN108138232A (en) | For diagnosing and assessing the method for nonalcoholic fatty liver disease | |
| Lancaster et al. | Alzheimer's disease risk variant in CLU is associated with neural inefficiency in healthy individuals | |
| Kanzaki et al. | Human nephron number, hypertension, and renal pathology | |
| Holle et al. | Serum indoxyl sulfate concentrations associate with progression of chronic kidney disease in children | |
| AU2020376239A1 (en) | Biomarkers and uses thereof for diagnosing the silent phase of alzheimer's disease | |
| Lippa et al. | Plasma tau and amyloid are not reliably related to injury characteristics, neuropsychological performance, or white matter integrity in service members with a history of traumatic brain injury | |
| US20190381070A1 (en) | Methods for Prophylactically Preventing, Slowing the Progression of, or Treating Cerebral Amyloid Angiopathy, Alzheimer's Disease and/or Acute Stroke | |
| CN114182007B (en) | Behcet disease marker gene and application thereof | |
| Hirai et al. | High-sucrose diets contribute to brain angiopathy with impaired glucose uptake and psychosis-related higher brain dysfunctions in mice | |
| Lecocq et al. | Aptamers as biomarkers for neurological disorders. Proof of concept in transgenic mice | |
| RU2425374C2 (en) | Device and method for quantitative analysis of polypeptide contained in body fluid sample, and also marker for detecting pathological states | |
| Timm et al. | Searching for novel biomarkers using a mouse model of CLN3-Batten disease | |
| CN111378733A (en) | Method for determining health food combination for neurodegenerative diseases and machine-readable storage medium thereof | |
| Kim et al. | Evaluation of nutritional status using bioelectrical impedance analysis in patients with inflammatory bowel disease | |
| Badji et al. | Cerebrospinal fluid biomarkers, brain structural and cognitive performances between normotensive and hypertensive controlled, uncontrolled and untreated 70-year-old adults | |
| Gassert et al. | SNR analysis of contrast-enhanced MR imaging for early detection of rheumatoid arthritis | |
| CN111192681A (en) | Method and system for acquiring target blood glucose characteristics | |
| Akatsu et al. | Iron deposition in autopsied liver specimens from older patients receiving intravenous iron infusion | |
| CN107217086B (en) | Disease marker and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200707 |
|
| WW01 | Invention patent application withdrawn after publication |